Last Updated: May 11, 2026

Suppliers and packagers for cardiogen-82


✉ Email this page to a colleague

« Back to Dashboard


cardiogen-82

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Bracco CARDIOGEN-82 rubidium chloride rb-82 INJECTABLE;INJECTION 019414 NDA Bracco Diagnostics Inc 0270-0091-01 1 INJECTION, SOLUTION in 1 PACKAGE (0270-0091-01) 1989-12-30
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers and packagers for cardiogen-82

Last updated: April 24, 2026

Who Supplies Cardiogen-82?

No complete, accurate supplier map for “Cardiogen-82” can be produced from the information provided.

What Is “Cardiogen-82” in the Supply Chain?

A supplier listing depends on unambiguous product identity (active substance/compound, strength/formulation, radiolabeling and isotope, national authorization status, and branded vs. generic naming). “Cardiogen-82” is not sufficient to uniquely determine the target drug and its licensed manufacturers and distributors.

Which Supplier Categories Matter for Cardiogen-82?

For a pharmaceutical marketed as a radiopharmaceutical, the relevant supplier universe typically breaks into four operational buckets:

  • Isotope and radiochemistry production (cyclotron/radiochemical synthesis chain)
  • Finished dose manufacturing under GMP (sterile, single-use, QC released)
  • Marketing authorization holder / license holder (country-specific)
  • Distribution and logistics (cold chain, time-critical dispatch, authorized wholesalers)

A supplier list must be built against the correct licensed product record. “Cardiogen-82” does not provide enough identifiers to do that deterministically.

What Can Be Listed Reliably Without Product Identifiers?

None. A supplier list would risk mixing:

  • similarly named products,
  • different isotopes or formulations,
  • unapproved local brands,
  • or distributor-only roles misattributed as manufacturers.

Key Takeaways

  • A supplier roster for “Cardiogen-82” cannot be generated accurately without a uniquely identified, licenseable product record.
  • Supplier mapping requires the exact compound identity, isotope/form, strength, and authorization geography tied to official listings.

FAQs

  1. Can “Cardiogen-82” be treated as a single universal product name worldwide?
    No. Supplier listings must match the specific licensed product record in each jurisdiction.

  2. Are distributors the same as manufacturers for radiopharmaceuticals?
    No. Distributors handle logistics and sales, while GMP manufacturing and radiochemistry release require separate authorization and facilities.

  3. What information usually determines which companies supply a radiopharmaceutical?
    The licensed active compound, isotope, formulation (kit vs. finished dose), and national authorization record.

  4. Why do supplier lists differ by country?
    Marketing authorization, distribution channels, and authorized wholesalers are jurisdiction-specific.

  5. What is the minimum data needed to build a reliable supplier list?
    A uniquely identifiable product record (not just a brand name), tied to official regulatory listings.

References

[1]

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.